$CMPS

3 theses

bullish 100%neutral 0%bearish 0%

Avg return (3m)

+22.1%

Win rate (3m)

100% (1 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Oct 23, 4:45 PM ET

$CMPSr/pennystocksStock Infobullish

u/JusaVaan · 15d agono track record yet

Compass Pathways (CMPS)-first FDA-approved psychedelic to market

CMPS's proprietary psilocybin therapy Comp360 is expected to receive FDA approval by end of 2024, likely within weeks. With a compressed timeline post-NDA submission, FDA Priority Voucher in hand, large successful Phase 3 trials, and a $1.5B market cap, the stock appears significantly undervalued relative to potential revenue from a 2-3% penetration of the 4M TRD patient market plus the 21M PTSD population.

At post $12.00Now $11.18-6.8% since postedas of Oct 23, 4:45 PM ET

1d—

3d-3.9%

1w-10.4%

1m—

3m—

6m—

1y—

original post →

$CMPSr/wallstreetbetsYOLObullish

u/UnfairRazzmatazz987 · 45d ago1 prior · 100% at 3mo

$CMPS Next Stop $30

Compass Pathways will break through $17 and rally to $30 based on positive after-hours price action.

At post $14.04Now $11.18-20.4% since postedas of Oct 23, 4:45 PM ET

1d+8.0%

3d+2.2%

1w-1.6%

1m-18.3%

3m—

6m—

1y—

original post →

$CMPSr/wallstreetbetsDiscussionbullish

u/UnfairRazzmatazz987 · 163d ago1 prior · 100% at 3mo

CMPS to $40 Is Starting to Look Very Real

CMPS is positioned to become a leader in psychedelic medicine with COMP360 in Phase 3 for treatment-resistant depression and FDA breakthrough therapy designation. Approval would unlock a massive new treatment category, making $40 a realistic target that still undervalues the company's market opportunity.

At post $10.96Now $11.18+2.0% since postedas of Oct 23, 4:45 PM ET

1d-3.1%

3d-5.4%

1w-0.8%

1m+10.2%

3m+22.1%

6m—

1y—

original post →

End of results.